CBT
Overvalued by 71.8% based on the discounted cash flow analysis.
Market cap | $5.29 Billion |
---|---|
Enterprise Value | $6.36 Billion |
Dividend Yield | $1.5878 (1.66%) |
Earnings per Share | $7.69 |
Beta | 1.25 |
Outstanding Shares | 55,430,710 |
Avg 30 Day Volume | 320,924 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 12.21 |
---|---|
PEG | -161.82 |
Price to Sales | 1.32 |
Price to Book Ratio | 4.03 |
Enterprise Value to Revenue | 1.62 |
Enterprise Value to EBIT | 11.33 |
Enterprise Value to Net Income | 14 |
Total Debt to Enterprise | 0.21 |
Debt to Equity | 0.99 |
No data
No data